Department of Gynecology and Obstetrics, University Hospital Marburg, Philipps-University Marburg, Marburg, Germany.
Oncology, IQVIA, Frankfurt Am Main, Germany.
J Cancer Res Clin Oncol. 2023 Aug;149(10):7319-7326. doi: 10.1007/s00432-023-04681-7. Epub 2023 Mar 15.
The aim of the study was to evaluate the baseline data of women with breast cancer (BC) undergoing treatment in an intercontinental comparison.
This study included 99,571 women with BC from Europe (70,834), Asia (18,208), and Latin America (10,529) enrolled between 2017 and 2021, based on data from IQVIA's Oncology Dynamics database. This source is supplied with information by means of a cross-sectional partially retrospective survey collecting anonymized data on inpatients and outpatients treated by a representative panel of oncologists. A multivariable logistic regression model was used to investigate the probability of metastases.
The data available in Asia (98%) and Latin America (100%) were hospital data, while in Europe, patients were treated both in hospitals and in office-based practices (62%, 38%). The mean age in Asia and Latin America (57 ± 13) was lower than in Europe (61 ± 13; p < 0.001). Lobular BC was diagnosed twice as often in Europe compared to Asia and Latin America (15.2%, 9.8%, 8.0%). The number of patients with metastasized hormone receptor-positive (HR +) BC was significantly higher in Europe and Latin America than in Asia (76%, 68%; p < 0.001). The highest number of women with metastasized BC was reported in Europe (26% compared to 14% and 20%, respectively, in Asia and Latin America). Across the continents, the percentage of women with BC who experienced metastases was 51-61% for bone, 30-39% for lung and 25-32% for liver, followed by 3-6% for skin and 3% for brain.
Women with BC treated in Europe tend to be significantly older and more likely to develop metastases than women in Asia and Latin America, except for lung metastases.
本研究旨在对接受跨洲际比较治疗的乳腺癌（BC）女性的基线数据进行评估。
本研究纳入了 2017 年至 2021 年期间来自欧洲（70834 例）、亚洲（18208 例）和拉丁美洲（10529 例）的 99571 例 BC 女性，其数据来源于 IQVIA 的 Oncology Dynamics 数据库。该数据库通过一项横断面部分回顾性调查提供信息，该调查收集了由代表性肿瘤学家小组治疗的住院患者和门诊患者的匿名数据。采用多变量逻辑回归模型研究转移的概率。
亚洲（98%）和拉丁美洲（100%）的数据为医院数据，而欧洲的数据则来源于医院和门诊实践（62%，38%）。亚洲和拉丁美洲的平均年龄（57±13）低于欧洲（61±13；p<0.001）。与亚洲和拉丁美洲相比，欧洲诊断为乳腺小叶癌的患者多两倍（15.2%、9.8%、8.0%）。欧洲和拉丁美洲转移性激素受体阳性（HR+）BC 患者的数量明显高于亚洲（76%、68%；p<0.001）。欧洲报告的转移性 BC 女性人数最多（26%，而亚洲和拉丁美洲分别为 14%和 20%）。在所有大陆，发生骨转移的 BC 女性比例为 51-61%，肺转移为 30-39%，肝转移为 25-32%，皮肤转移为 3-6%，脑转移为 3%。
与亚洲和拉丁美洲的女性相比，接受治疗的欧洲 BC 女性年龄明显更大，且发生转移的可能性更高，除了肺转移。
